ASCO 2025: Dr. Singhi Shares Key Lung Cancer Studies to Watch

Eric Singhi, MD, of the University of Texas MD Anderson Cancer Center, joined Lung Cancers Today to discuss what he’s looking forward to at the American Society of Clinical Oncology (ASCO) Annual Meeting.

“I’m very excited to be invited this year as faculty for ASCO 2025, the largest annual cancer conference,” Dr. Singhi explained.

With the wealth of data to be presented at the annual meeting, Dr. Singhi explained that there are multiple “potentially practice-changing studies in thoracic oncology” that he’s watching.

In small cell lung cancer, Dr. Singhi said he’s looking forward to the presentation of the IMFORTE study, which is evaluating the addition of lurbinectedin to atezolizumab in the first-line maintenance setting for patients with extensive-stage small cell lung cancer.

“We’ve heard in a press release that there is a clinically meaningful benefit with the addition of lurbinectedin in that setting,” Dr. Singhi said. “It’ll be exciting to see exactly who’s benefiting and what that benefit is.”

In non–small cell lung cancer (NSCLC), Dr. Singhi explained that there are “some potentially exciting updates in the neoadjuvant space.”

“We are going to hear about the overall survival update for CheckMate 816, which was a phase 3 study looking at chemoimmunotherapy in the neoadjuvant setting before patients go for surgical resection,” Dr. Singhi said, explaining that a press release previously showed there was an overall survival benefit, “which is huge news to have that overall survival benefit for a neoadjuvant-only regimen.”

He also highlighted the NeoADAURA study, which is evaluating osimertinib plus or minus chemotherapy in the neoadjuvant setting for patients with surgically resectable EGFR-positive NSCLC.

Beyond the data, Dr. Singhi said that the annual meeting is a critical opportunity to make new connections with colleagues and build upon existing ones.

“If I’ve connected with you… through social media, through other avenues, please reach out, say hi,” Dr. Singhi said. “I would love to build and continue to build those network relationships with people.”